Cartesian Therapeutics appoints Adrian Bot to board; brings CAR T and RNA therapy expertise

Cartesian Therapeutics, Inc.

Appointed Adrian Bot, M.D., Ph.D., as Class II director effective Dec 16, 2025; will serve on Science and Technology Committee.
Bot brings three decades of R&D experience in CAR T, cell/gene therapy and nanomedicines; former CSO of Capstan Therapeutics.
Initial compensation includes option for 17,200 shares at $8.29 and RSUs for 5,800 shares, with multi-year vesting schedules.
CEO highlights Bot's role in first-in-class CAR T therapies and Capstan's acquisition by Abbvie, relevant to Cartesian's autoimmunity focus.
Company is a clinical-stage biotech advancing cell therapy for autoimmune diseases; expects a critical year of execution.

item 5.02 item 5.05 item 7.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000140
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-12-18T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.444894+00:00
generated_at: 2026-05-16T12:43:39.882220+00:00
sec_items: ["5.02", "5.05", "7.02", "7.01", "9.01"]
event_type: leadership
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000140
json_url: https://secwatch.observer/filing/0001453687-25-000140.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000140.md
text_url: https://secwatch.observer/filing/0001453687-25-000140.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/0001453687-25-000140-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000140/rnac-20251216.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-25-000140

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.